Franklin Genomic Advancements ETF (HELX) seeks to track companies developing breakthrough technologies in genomics, gene therapy, and precision medicine. This thematic healthcare ETF targets firms advancing DNA sequencing, CRISPR gene editing, personalized treatments, and biotechnology innovations that could revolutionize medical care.
How It Works
HELX uses an actively managed approach to select companies across the genomic advancement value chain, from research tools and diagnostics to therapeutic development and data analytics. The fund focuses on pure-play genomics companies and established healthcare firms with significant genomic divisions. Portfolio construction emphasizes growth potential and innovation leadership rather than traditional valuation metrics, with quarterly rebalancing to capture emerging opportunities in this rapidly evolving sector.
Key Features
- Pure-play exposure to genomics revolution including CRISPR, gene therapy, and precision medicine companies often unavailable in broad healthcare ETFs
- Active management allows rapid adaptation to breakthrough technologies and regulatory approvals that passive genomics indexes cannot quickly capture
- Targets high-growth biotech innovators alongside established pharmaceutical giants investing heavily in genomic research and development
Risks
- This ETF can lose significant value if genomic therapies face regulatory setbacks or clinical trial failures, potentially declining 40-60% during biotech bear markets
- Concentrated exposure to early-stage companies means individual stock failures can dramatically impact performance, with some holdings potentially losing 80-90% of value
- Thematic investing risk exists if genomics adoption proves slower than expected or alternative medical technologies emerge as superior solutions
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for aggressive growth investors with 7+ year time horizons and high risk tolerance. Appropriate for investors seeking exposure to healthcare innovation beyond traditional pharmaceutical companies. Requires patience for long drug development cycles and regulatory approval processes inherent in genomics investing.